Discover why tirzepatide is more than “another GLP‑1.” Learn how its dual GIP/GLP‑1 agonism, advanced peptide engineering, and once‑weekly dosing deliver deeper glucose control, powerful weight loss, and broad metabolic benefits compared to traditional GLP‑1 drugs.
Discover how orforglipron, a first‑in‑class oral GLP‑1 receptor agonist, delivers injectable‑level weight loss and glycemic control in a once‑daily pill, with phase 2 data in obesity and type 2 diabetes.